Compare Stocks → A lot of people are making this costly mistake (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BLUSFNASDAQ:CLINNASDAQ:FATENASDAQ:RARX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsCLINClean Earth Acquisitions$0.43+4.9%$6.76$4.54▼$11.36$7.15M-0.1478,528 shs109,447 shsFATEFate Therapeutics$7.34$6.70$1.63▼$8.83$728.42M1.672.95 million shs2.72 million shsRARXRa Pharmaceuticals$47.99$47.99$19.64▼$48.02$2.27B1.051.16 million shs30,200 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%+106.44%CLINClean Earth Acquisitions-2.20%-12.96%-3.51%-72.70%-96.01%FATEFate Therapeutics0.00%-1.21%-1.61%+96.26%+32.25%RARXRa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Grab Your Free Bitcoin Today! (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUSFBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/ACLINClean Earth AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/AFATEFate Therapeutics3.5611 of 5 stars2.02.00.04.73.22.50.6RARXRa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUSFBELLUS HealthN/AN/AN/AN/ACLINClean Earth AcquisitionsN/AN/AN/AN/AFATEFate Therapeutics2.09Hold$6.73-8.35% DownsideRARXRa PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest CLIN, FATE, CUV, RARX, and BLUSF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024FATEFate TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$2.00 ➝ $6.003/19/2024FATEFate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$7.002/27/2024FATEFate TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $7.002/27/2024FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$6.00 ➝ $10.002/27/2024FATEFate TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Perform ➝ Market Perform$6.00 ➝ $7.002/27/2024FATEFate TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $7.002/27/2024FATEFate TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00CLINClean Earth AcquisitionsN/AN/AN/AN/AN/AN/AFATEFate Therapeutics$63.53M11.47N/AN/A$3.74 per share1.96RARXRa Pharmaceuticals$3M757.11N/AN/A$5.56 per share8.63Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/ACLINClean Earth AcquisitionsN/AN/A0.00∞N/AN/AN/AN/AN/AFATEFate Therapeutics-$160.93M-$1.64N/AN/AN/A-253.30%-38.17%-28.42%5/1/2024 (Estimated)RARXRa Pharmaceuticals-$102.69M-$2.31N/AN/AN/AN/A-44.61%-41.60%N/ALatest CLIN, FATE, CUV, RARX, and BLUSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/202412/31/2023FATEFate Therapeutics-$0.57-$0.45+$0.12-$0.45$0.85 million$1.68 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUSFBELLUS HealthN/AN/AN/AN/AN/ACLINClean Earth AcquisitionsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/ARARXRa PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUSFBELLUS HealthN/A13.8713.87CLINClean Earth AcquisitionsN/AN/AN/AFATEFate TherapeuticsN/A8.488.48RARXRa Pharmaceuticals0.0114.7814.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUSFBELLUS HealthN/ACLINClean Earth Acquisitions26.39%FATEFate Therapeutics97.54%RARXRa PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBLUSFBELLUS Health24.17%CLINClean Earth Acquisitions24.27%FATEFate Therapeutics5.04%RARXRa Pharmaceuticals4.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableCLINClean Earth AcquisitionsN/A16.70 million12.65 millionNot OptionableFATEFate Therapeutics18199.24 million94.24 millionOptionableRARXRa Pharmaceuticals7247.33 millionN/AOptionableCLIN, FATE, CUV, RARX, and BLUSF HeadlinesSourceHeadlineDrug Insight: Tumor Necrosis Factor Converting Enzyme as a Pharmaceutical Target for Rheumatoid Arthritismedscape.com - February 4 at 9:15 AMRA: Discount Continues To Leave Some Opportunityseekingalpha.com - January 23 at 12:36 PMFusion Pharma marks in-house radiopharma manufacturing success, details PhII/III trial studyendpts.com - January 5 at 12:00 PMAmon-Ra St. Brown pays off friendly wager he quips was made 'outside the facility'freep.com - November 9 at 8:48 AMDetroit Lions game balls and goats: Amon-Ra St. Brown delivers; DBs need to be betterfreep.com - November 7 at 8:15 AMDetroit Lions No. 1 WR Amon-Ra St. Brown doubtful to play against Carolina Panthersfreep.com - October 27 at 2:48 PMImperial Petroleum, ARS Pharmaceuticals Stock, and More See Action From Activist Investorsbarrons.com - September 8 at 7:52 PMAnthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public Offeringthestreet.com - May 29 at 11:21 AMCourt rules for drugmakers in 340B fight over contract pharmaciesbiopharmadive.com - January 31 at 11:36 PMUPDATE 1-AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln dealmsn.com - January 10 at 12:36 PMAstraZeneca to buy CinCor Pharma in $1.8 billion dealpoandpo.com - January 9 at 10:19 AMAstraZeneca launching offer to acquire blood pressure drug developer for initial price of $1.3 billiondelawarebusinessnow.com - January 9 at 10:19 AMAstraZeneca to buy U.S.-based CinCor Pharma in $1.8 billion dealwdez.com - January 9 at 10:19 AMJanuary’s new drug price increases take off without overcompensating for upcoming inflation-linked rebatesendpts.com - January 4 at 3:18 PMNovartis offloads five eye drugs in deal worth up to $175Mendpts.com - December 14 at 2:04 PMRA Capital Closes Position in Astria Therapeutics (ATXS)247wallst.com - November 15 at 3:32 PMRARX_old Historical Datainvesting.com - August 20 at 6:18 PMPhilly-area pharma firm raises $118M for high blood pressure drugmsn.com - June 12 at 10:54 AMPhilly-area pharma firm raises $118M for high blood pressure drug for those who need extra helpmsn.com - June 8 at 9:49 AMRa Medical Systems Reports First Quarter 2022 Financial Resultsfinance.yahoo.com - May 16 at 5:54 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Google and Meta Circling the Market on a TikTok Ban RallyMarch 21, 2024 12:58 PMView Google and Meta Circling the Market on a TikTok Ban RallyS&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?March 18, 2024 8:38 AMView S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?Hershey Stock Decline: An Opportunity for Investors to BuyMarch 27, 2024 7:21 AMView Hershey Stock Decline: An Opportunity for Investors to BuyAll Headlines Company DescriptionsBELLUS HealthOTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Clean Earth AcquisitionsNASDAQ:CLINClean Earth Acquisitions Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring companies in the clean energy ecosystem, including carbon, hydrogen, sustainable agriculture, and renewable energy. The company was incorporated in 2021 and is based in Bee Cave, Texas.Fate TherapeuticsNASDAQ:FATEFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Ra PharmaceuticalsNASDAQ:RARXRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.